Low Risk Myelodysplastic Syndromes
Oncology·MeSH: Myelodysplastic Syndromes
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| r906289 mono | RIGEL PHARMACEUTICALS INC (RIGL) |
Frequently asked questions
How many drugs are in development for Low Risk Myelodysplastic Syndromes?
BioSniper tracks 1 drug in development for Low Risk Myelodysplastic Syndromes across 1 company.
How many clinical trials target Low Risk Myelodysplastic Syndromes?
There are 1 clinical trial targeting Low Risk Myelodysplastic Syndromes tracked by BioSniper.
What is the prevalence of Low Risk Myelodysplastic Syndromes?
The estimated prevalence of Low Risk Myelodysplastic Syndromes is approximately 5.0 per 100,000 population.
Deep-dive into Low Risk Myelodysplastic Syndromes
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis